Gratomic and Perpetuus Carbon Technologies Limited Enter Into an Agreement for the Exclusive Development and Marketing of Material Enhancing Graphenes Derived From Gratomic Aukam Graphite
TORONTO, April 23, 2018 (GLOBE NEWSWIRE) -- Gratomic Inc. ("GRAT" or the "Company") (TSX-V:GRAT) (FRANKFURT:CB81) (WKN:A2JAP3).
Gratomic Inc., is pleased to announce that the Company has signed a letter of collaboration ("Agreement") with Perpetuus Carbon Technologies Limited ("Perpetuus") pursuant to which GRAT and Perpetuus will develop and market material enhancing graphite derived graphenes and graphene hybrids for tire elastomers, whilst also exploring options to exploit polymer composites, energy capture and storage applications markets ("Project").
The Agreement contemplates the first Phase of the Project ("Phase 1"), with the other phases to be described in a joint venture agreement to be entered into between GRAT and Perpetuus.
Pursuant to the Agreement, and as part of Phase 1, GRAT will purchase, and retain ownership, of three specialised process tooling chambers at an aggregate cost of 300,000 British Pounds. These specialized tooling chambers will be housed in Perpetuus' existing facility in the United Kingdom. In addition to housing the specialized tooling chambers Perpetuus will contribute its Patented Project specific intellectual property, designed perfected and engineered by Perpetuus. In addition Perpetuus will also manage and maintain the specialized tooling chambers.
The Agreement contemplates the supply of Graphite from the Aukam Graphite mine in Namibia.
GRAT and Perpetuus will share equally all proceeds of sales after deductions of operating costs and Product purchasing costs.
Gratomic's Chairman and CO-CEO Sheldon Inwentash stated:
I am extremely pleased to announce that the Gratomic Perpetuus agreement completes the first stage of the Gratomic strategic plan to establish the first vertically integrated Graphite to Graphene to mass market product.
Ian Walters Director - Perpetuus Carbon Technologies Limited stated:
On road trials in the UK it has been duly established that the extra ordinary properties of the Gratomic Aukam Graphite derived graphenes provide enhancing properties for tire elastomer tread formulations. These conclusions are scientifically evidenced and duly recorded by the fact that the graphene enhanced tire tread significantly out performs a comparative size but more expensive premier branded Tire. We can only conclude that the Gratomic Tire due to be launched later this year is well placed to revolutionise the commercial Tire market and establish the first Graphite mine to commercial exploitation "vertical" for graphenes derived from mined graphite.
About Gratomic Inc.
Gratomic Inc. is an advanced materials company focused on mine to market commercialization of graphite products most notably high value graphene based components for a range of mass market products.
"Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release."
FORWARD LOOKING STATEMENTS: This news release contains forward-looking statements, which relate to future events or future performance and reflect management's current expectations and assumptions. Such forward-looking statements reflect management's current beliefs and are based on assumptions made by and information currently available to the Company. Investors are cautioned that these forward-looking statements are neither promises nor guarantees and are subject to risks and uncertainties that may cause future results to differ materially from those expected. These forward-looking statements are made as of the date hereof and, except as required under applicable securities legislation, the Company does not assume any obligation to update or revise them to reflect new events or circumstances. All of the forward-looking statements made in this press release are qualified by these cautionary statements and by those made in our filings with SEDAR in Canada (available at www.sedar.com).
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Gratomic via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Anima Biotech Named U.S. Deal of the Year Winner at Lifestars™ Life Science Awards20.11.2018 16:17 | Pressemelding
Award recognizes the transformative potential of Anima’s $1B+ collaboration with Lilly BERNARDSVILLE, N.J., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Anima Biotech, the leader in the discovery of drugs that specifically control protein translation, has been named winner of the “U.S. Deal of the Year” award at the 2018 Lifestars AwardsTM. “We are delighted to receive this award, which recognizes the power and potential of our Translation Control Therapeutics platform,” said Yochi Slonim, co-founder and chief executive officer of Anima Biotech. “Our deal with Lilly further validates our approach and our partnering strategy of creating exclusive collaborations around our partners’ chosen targets.” “Lifestars presented a fantastic opportunity to bring together a deserved audience and highlight the advances being made in our industry. It’s a testament to Anima Biotech’s efforts that this year’s judging faculty commended them in this manner,” said Neil Darkes, Co-CEO, LSX Ltd. And Lifestars. The int
Cernostics Secures Additional Patents for Proprietary Barrett’s Esophagus Clinical Diagnostics20.11.2018 15:00 | Pressemelding
US and EU patents for TissueCypher® cover methods for detecting risk of progression to esophageal cancer in Barrett’s esophagus patients PITTSBURGH, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Cernostics, developer of next-generation cancer diagnostics and prognostics, announced that it has received a U.S. Patent and a European Notice to Grant for the company’s TissueCypher® Barrett’s Esophagus Assay, adding protection to previously awarded foundational, platform patents granted in 2014. Earlier this month, Cernostics received notification from the European Patent Office that claims will be issued for its patent entitled “Systems and Compositions for Diagnosing Barrett’s Esophagus and Methods for Using the Same.” This notice comes on the heels of a recent issuance of a corresponding U.S. patent (U.S. Patent No. 10,018,631). Cernostics’ recent patent claims relate to the company’s clinical test for predicting disease progression in patients with BE and assessment of the likelihood that BE may fur
Gratomic Announces Over-Subscription Non-Brokered Private Placement20.11.2018 14:00 | Pressemelding
TORONTO, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Gratomic Inc. (“GRAT” or the “Company”) (TSX-V: GRAT) (FRANKFURT:CB81, WKN:A143MR) is pleased to announce that the offering of a non-brokered private placement announced on November 16, 2018 has been over-subscribed and the Company will be offering up to 20,000,000 working capital units (the “WC Unit”) for up to $2,000,000 (the “Offering”). Each WC Unit is priced at $0.10 and consists of one (1) common share and one (1) common share purchase warrant (“WC Warrant”). Each WC Warrant entitles the holder to purchase one (1) common share (a “WC Warrant Share”) at a price of $0.20 per WC Warrant Share until the earlier of: (i) three (3) years following the Closing of the Offering; and (ii) in the event that the closing price of the Common Shares on the TSX Venture Exchange is at least $0.30 for ten (10) consecutive trading days, and the 10th trading day (the “Final Trading Day”) is at least four (4) months from the Closing Date, the date which is th
Ondot Systems Named One of North America’s Fastest Growing Companies in Deloitte’s 2018 Technology Fast 500™20.11.2018 14:00 | Pressemelding
Ranked Fastest Growing FinTech Company in Silicon Valley with 224 percent revenue growth and over four thousand Financial Institutions now offering its white label service Santa Clara, California, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Ondot Systems, the leading provider of Digital Card Services and Customer Empowerment Solutions, today announced that it was named by Deloitte’s Technology Fast 500TM as the fastest growing Silicon Valley FinTech company, and one of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North America. A recent report “Accelerating Digital Transformation in Banking” published by Deloitte on results of a survey of 17,100 consumers across 17 countries concluded that leading technology companies have become the gold standard for digital engagement, thus driving a stronger emotional connection for consumers with these brands over their primary banks. If banks want to keep up, they must engineer their digital exper
Patton Delivers IPv6 Services at the Network Edge20.11.2018 13:15 | Pressemelding
Implementing enhanced IPv6 in SmartNode VoIP CPE, Patton supports simplified network architectures and lowers operation and maintenance costs for service providers and enterprises. SmartNode VoIP… More than Just Talk! GAITHERSBURG, Md., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Patton Electronics—doing business as a bricks-and-mortar manufacturer since 1984—has enhanced IPv6 in its SmartNode CPE, the company announced today. Global expansion of the Internet, proliferation of IP endpoint devices, and the burgeoning Internet of Things (IoT) means we will soon run out of IPv4 addresses. The IPv6 standard expands available IP addresses octillion times, or at least 17 billion . Everyone has known that for a long time and the hype has been going on for years. Service providers made plans, and some partially implemented IPv6 in their networks. Carriers like Telefonica and T-MOBILE—and enterprises such as Microsoft—have started the changeover. Many large enterprises also planned on it, but have spotty
SoftServe Achieves ISO 13485 Standard for Medical Device Quality Management Systems20.11.2018 13:00 | Pressemelding
International standard ensures customer and regulatory requirements are consistently met for the lifecycle of medical device products AUSTIN, Texas, Nov. 20, 2018 (GLOBE NEWSWIRE) -- SoftServe, a leading digital authority and consulting company, announces it has achieved the ISO 13485:2016 standard – an internationally recognized standard that defines quality management system requirements for medical device manufacturers as set by the International Organization for Standardization (ISO). SoftServe implemented and established a quality management system compliant with the requirements of ISO 13485:2016. This activity was verified by third-party audits by Loyd’s Register, an accredited certification company. One critical advantage of the certification is it cultivates a preventative approach to assure software medical device quality versus a reactive approach of inspection and rejection during production. “With software as a medical device and software in a medical device continuing to
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom